Your browser doesn't support javascript.
U-shaped association between abnormal serum uric acid levels and COVID-19 severity: reports from the Japan COVID-19 Task Force.
Fukushima, Takahiro; Chubachi, Shotaro; Namkoong, Ho; Otake, Shiro; Nakagawara, Kensuke; Tanaka, Hiromu; Lee, Ho; Morita, Atsuho; Watase, Mayuko; Kusumoto, Tatsuya; Masaki, Katsunori; Kamata, Hirofumi; Ishii, Makoto; Hasegawa, Naoki; Harada, Norihiro; Ueda, Tetsuya; Ueda, Soichiro; Ishiguro, Takashi; Arimura, Ken; Saito, Fukuki; Yoshiyama, Takashi; Nakano, Yasushi; Mutoh, Yoshikazu; Suzuki, Yusuke; Murakami, Koji; Okada, Yukinori; Koike, Ryuji; Kitagawa, Yuko; Kimura, Akinori; Imoto, Seiya; Miyano, Satoru; Ogawa, Seishi; Kanai, Takanori; Fukunaga, Koichi.
  • Fukushima T; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Chubachi S; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan. Electronic address: bachibachi472000@live.jp.
  • Namkoong H; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Otake S; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Nakagawara K; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Tanaka H; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Lee H; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Morita A; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Watase M; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Kusumoto T; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Masaki K; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Kamata H; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Ishii M; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Hasegawa N; Department of Infectious Diseases, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Harada N; Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.
  • Ueda T; Department of Respiratory Medicine, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
  • Ueda S; JCHO (Japan Community Health Care Organization) Saitama Medical Center, Internal Medicine, Saitama, Japan.
  • Ishiguro T; Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Kumagaya, Japan.
  • Arimura K; Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan.
  • Saito F; Department of Emergency and Critical Care Medicine, Kansai Medical University General Medical Center, Moriguchi, Japan.
  • Yoshiyama T; Department of Respiratory Medicine, Fukujuji hospital, Kiyose, Japan.
  • Nakano Y; Department of Internal Medicine, Kawasaki Municipal Ida Hospital, Kawasaki, Japan.
  • Mutoh Y; Department of Infectious Diseases, Tosei General Hospital, Seto, Japan.
  • Suzuki Y; Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
  • Murakami K; Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Okada Y; Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan; Department of Genome Informatics, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan; Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
  • Koike R; Medical Innovation Promotion Center, Tokyo Medical and Dental University, Tokyo, Japan.
  • Kitagawa Y; Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
  • Kimura A; Institute of Research, Tokyo Medical and Dental University, Tokyo, Japan.
  • Imoto S; Division of Health Medical Intelligence, Human Genome Center, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan.
  • Miyano S; M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan.
  • Ogawa S; Department of Pathology and Tumor Biology, Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan; Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden.
  • Kanai T; Division of Gastroenterology and Hepatology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Fukunaga K; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Int J Infect Dis ; 122: 747-754, 2022 Sep.
Article in English | MEDLINE | ID: covidwho-1983199
ABSTRACT

OBJECTIVES:

This study aimed to identify the relationship between abnormal serum uric acid levels or a history of hyperuricemia and COVID-19 severity in the Japanese population.

METHODS:

We included 1523 patients enrolled in the Japan COVID-19 Task Force cohort between February 2020 and May 2021. We compared the clinical characteristics, including co-morbidities, laboratory findings, and outcomes, particularly invasive mechanical ventilation (IMV), among patients with and without abnormal uric acid levels or a history of hyperuricemia.

RESULTS:

Patients with high serum uric acid levels were older and had higher body weight and body mass index than those without. In addition, the multiple logistic regression analysis revealed a significant association between high serum uric acid levels or a history of hyperuricemia and an increased risk of IMV (odds ratio [OR] = 1.77; P = 0.03/OR = 1.56; P = 0.04). Moreover, patients with low uric acid levels on admission were also associated significantly with the requirement of IMV (OR = 5.09; P <0.0001).

CONCLUSION:

Abnormal serum uric acid levels or a history of hyperuricemia were significantly associated with COVID-19 severity in the Japanese cohort.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hyperuricemia / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Limits: Humans Country/Region as subject: Asia Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: J.ijid.2022.07.014

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Hyperuricemia / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Limits: Humans Country/Region as subject: Asia Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: J.ijid.2022.07.014